Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey
Rhiannon Bath, Tanner Bucholz, Amy Buros, et al.
Journal of Addiction Medicine (2019) Vol. 14, Iss. 3, pp. 244-252
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations
Christopher R. McCurdy, Abhisheak Sharma, Kirsten E. Smith, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 2, pp. 131-142
Closed Access | Times Cited: 18
Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use
Kirsten E. Smith, Jeffrey M. Rogers, Destiny Schriefer, et al.
Drug and Alcohol Dependence (2021) Vol. 226, pp. 108879-108879
Open Access | Times Cited: 56
Understanding Kratom Use: A Guide for Healthcare Providers
Marc T. Swogger, Kirsten E. Smith, Albert Garcia‐Romeu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
Prevalence of Kratom Use Disorder Among Kratom Consumers
Katherine Hill, Oliver Grundmann, Kirsten E. Smith, et al.
Journal of Addiction Medicine (2024) Vol. 18, Iss. 3, pp. 306-312
Closed Access | Times Cited: 9
Kratom use as more than a “self-treatment”
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 6, pp. 684-694
Closed Access | Times Cited: 37
Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review
Elisabeth Prevete, Kim P. C. Kuypers, Eef L. Theunissen, et al.
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 317-334
Open Access | Times Cited: 17
Growing pains with kratom: experiences discussed in subreddits contrast with satisfaction expressed in surveys
Jeffrey M. Rogers, Kayla Colvin, David H. Epstein, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.
Kirsten E. Smith, Kelly E. Dunn, Oliver Grundmann, et al.
Experimental and Clinical Psychopharmacology (2021) Vol. 30, Iss. 6, pp. 983-996
Open Access | Times Cited: 40
When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use
Kirsten E. Smith, Jeffrey M. Rogers, Justin C. Strickland, et al.
The American Journal of Drug and Alcohol Abuse (2021) Vol. 47, Iss. 4, pp. 455-466
Open Access | Times Cited: 37
Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey.
Oliver Grundmann, Charles A. Veltri, Sara Morcos, et al.
Experimental and Clinical Psychopharmacology (2023) Vol. 31, Iss. 5, pp. 963-977
Open Access | Times Cited: 14
The Potential for Kratom as an Antidepressant and Antipsychotic.
Lindsay E Johnson, Lilian Balyan, Amy Magdalany, et al.
(2020) Vol. 93, Iss. 2, pp. 283-289
Closed Access | Times Cited: 37
A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans
Elisabeth Prevete, Kim P. C. Kuypers, Eef L. Theunissen, et al.
Human Psychopharmacology Clinical and Experimental (2021) Vol. 37, Iss. 1
Open Access | Times Cited: 32
Mitragyna Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products
Islamudin Ahmad, Wisnu Cahyo Prabowo, Muhammad Arifuddin, et al.
Life (2022) Vol. 12, Iss. 2, pp. 193-193
Open Access | Times Cited: 19
Cross- Sector Collaboration in Addressing Stunting in Indonesia
Misrawatie Goi, Andi Ummu Salmah, Nurhaedar Jafar, et al.
Pharmacognosy Journal (2025) Vol. 16, Iss. 6, pp. 1424-1430
Open Access
Cytotoxic Potential of Mitragyna speciosa as Anticancer - A Review
Puja Adi Priatna, Retno Widyowati, Sukardiman S Sukardiman
Pharmacognosy Journal (2025) Vol. 16, Iss. 6, pp. 1418-1423
Open Access
At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use
Katherine Hill, Jeffrey M. Rogers, Oliver Grundmann, et al.
The American Journal of Drug and Alcohol Abuse (2025), pp. 1-13
Open Access
Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample
Jeffrey M. Rogers, Kirsten E. Smith, Justin C. Strickland, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 25
Kratom’s Emergence and Persistence Within the US Polydrug Epidemic
Kirsten E. Smith, Jeffrey M. Rogers, Jeffrey D. Feldman
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 262-271
Open Access | Times Cited: 10
Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis
Elisabeth Prevete, Aleksi Hupli, Shanna Marrinan, et al.
Emerging Trends in Drugs Addictions and Health (2021) Vol. 1, pp. 100007-100007
Open Access | Times Cited: 19
How Essential is Kratom Availability and use during COVID-19? Use Pattern Analysis Based on Survey and Social Media Data
Oliver Grundmann, Charles A. Veltri, Diana Morcos, et al.
Substance Abuse (2022) Vol. 43, Iss. 1, pp. 865-877
Open Access | Times Cited: 13
Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study
Antonio Metastasio, Elisabeth Prevete, Darshan Singh, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 19
Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors
Katherine Hill, Stephen Gibson, Oliver Grundmann, et al.
Substance Abuse Treatment Prevention and Policy (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 6
Kratom exposures among older adults reported to U.S. poison centers, 2014–2019
Janessa M. Graves, Julia A. Dilley, Lucia Terpak, et al.
Journal of the American Geriatrics Society (2021) Vol. 69, Iss. 8, pp. 2176-2184
Closed Access | Times Cited: 15
Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic
David Adzrago, Elizabeth O. Obekpa, Tiffany Suragh, et al.
Drug and Alcohol Dependence (2022) Vol. 239, pp. 109605-109605
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top